8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Oct 28, 2014)

Filed October 28, 2014For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on October 28, 2014, to report its financial results for the third quarter of 2014. The key information is contained within an accompanying press release, which is incorporated by reference into the filing. This press release details the company's performance and financial condition for the period ending September 30, 2014. Investors should refer to the press release (Exhibit 99) for specific financial data, including revenue, earnings per share, and any forward-looking guidance provided by management. While the 8-K itself is a formal notification, the substance of the financial results and operational updates are found in the referenced press release, making it the primary document for analysis of Pfizer's Q3 2014 performance.

Key Highlights

  • 1Pfizer Inc. announced its third-quarter 2014 financial results via an 8-K filing on October 28, 2014.
  • 2The press release containing the detailed financial results for Q3 2014 is incorporated by reference as Exhibit 99.
  • 3The filing serves as the official notification of the company's financial performance for the period.
  • 4Investors and analysts should review the Exhibit 99 press release for specific financial figures and operational commentary.
  • 5The event date for the results being reported was October 27, 2014.
  • 6The filing was signed by Atiba D. Adams, Vice President and Corporate Secretary.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally report Pfizer Inc.'s financial results for the third quarter of 2014. The detailed results are provided in an attached press release.

The actual financial results and related commentary are located in the press release attached as Exhibit 99 to this 8-K filing. This press release is incorporated by reference and contains the specific financial data.

This specific 8-K filing, dated October 28, 2014, primarily focuses on the reporting of third-quarter 2014 financial results. Any strategic announcements or business updates would typically be found within the content of the Exhibit 99 press release or in separate filings if they are significant enough.

Atiba D. Adams is listed as Vice President and Corporate Secretary for Pfizer Inc. Their signature on the 8-K filing indicates that the report has been duly authorized and submitted on behalf of the company as required by the Securities Exchange Act of 1934.